Actively Recruiting

Phase 1
Phase 2
Age: 25Years - 59Years
All Genders
ID07429253

Comparative Effectiveness of Secretome Injection and Intradermal Platelet-Rich Plasma Injection on Hair Density and Terminal-to-Vellus Hair Ratio in Patients With Androgenetic Alopecia

Led by PT. Prodia Stem Cell Indonesia · Updated on 2026-02-24

40

Participants Needed

1

Research Sites

13 weeks

Total Duration

On this page

Sponsors

P

PT. Prodia Stem Cell Indonesia

Lead Sponsor

R

RS Prof. Dr. I.G.N.G Ngoerah

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are comparing two injection treatments, secretome and intradermal platelet-rich plasma (PRP), to see how they affect hair density and the ratio of terminal to vellus hairs in people with androgenetic alopecia. This randomized controlled clinical study takes place at Prof. Dr. I.G.N.G. Ngoerah General Hospital and focuses on adults aged 25 to 59 years with specific stages of hair loss. The purpose is to evaluate which treatment better supports hair growth and density. Participants receive either umbilical cord mesenchymal stem cell-derived secretome or platelet-rich plasma injections. Both treatments involve intradermal injections spaced 1 cm apart at the alopecia site and are administered every 2 weeks for a total of 8 weeks. The secretome and PRP injections are given under controlled conditions, with patients randomly assigned to one of the two groups. During the study, hair density and the terminal-to-vellus hair ratio are measured before treatment, at 8 weeks after intervention, and again during follow-up visits at months 3, 6, and 9. Evaluations use trichoscopy or dermoscopy to monitor changes. Participants provide informed consent and are monitored throughout the study to track treatment effects and safety. The total study duration includes treatment and follow-up periods to assess long-term outcomes.

CONDITIONS

Brief Title

Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients

Who Can Participate

Age: 25Years - 59Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male patients aged 25 to 59 years with androgenetic alopecia and Hamilton-Norwood grades II to VI
  • Female patients aged 25 to 59 years with androgenetic alopecia and Ludwig grades I to III
  • Female patients who are not currently pregnant or breastfeeding
  • Patients who have stopped anti-androgen medications and minoxidil for at least 1 month prior to treatment
  • Patients without allergies to secretome components or platelet-rich plasma preparation materials
  • Patients able to understand Indonesian and willing to provide written informed consent
Not Eligible

You will not qualify if you...

  • Patients unable to understand Indonesian or unwilling to provide written informed consent
  • Patients with hair loss types other than androgenetic alopecia
  • Patients currently using 5-alpha reductase inhibitors
  • Patients who have received intradermal corticosteroid scalp injections within the past 6 months
  • Patients with active scalp infections or dermatitis
  • Patients allergic to secretome components or platelet-rich plasma preparation materials
  • Patients with a history of hypertrophic scarring or blood clotting disorders
  • Patients unable to complete all study procedures

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - 8 weeks

Participants receive intradermal injections of either UC-MSC secretome or platelet-rich plasma to the scalp at the alopecia site, administered every 2 weeks for 8 weeks.

4 visits (in-person) every 2 weeks

Follow-up

Duration - 7 months

Participants are monitored for hair density and terminal-to-vellus hair ratio at 3, 6, and 9 months after treatment.

3 visits (in-person) at months 3, 6, and 9

Trial Site Locations

Total: 1 location

1

Prof. dr. I.G.N.G. Ngoerah Central General Hospital

Denpasar, Bali, Indonesia, 80113

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

DOUBLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

A Pilot Study Evaluating the Safety and Efficacy of a 1470nm...

Scarring Alopecia

Actively Recruiting

1 location

A Multicenter, Randomized, Double-Blind, Placebo-Controlled ...

Androgenetic Alopecia

Actively Recruiting

1 location

National, Multicentre, Randomized, Double-blind, Double-dumm...

Androgenetic Alopecia

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here